These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Mebhydrolin napadisylate. A possible cause of reversible agranulocytosis and neutropenia.
    Author: McEwen J, Strickland WJ.
    Journal: Med J Aust; 1982 Nov 27; 2(11):523-5. PubMed ID: 6130466.
    Abstract:
    Mebhydrolin napadisylate is an antihistamine marketed in Australia as Fabahistin, and as an ingredient of Fabahistin Plus. Since June, 1973, 11 Australian reports associating this drug with either agranulocytosis or neutropenia have been received by the Adverse Drug Reactions Advisory Committee. In seven of these reports, mebhydrolin napadisylate was the only suspected drug. These reactions are probably uncommon, but the association should be borne in mind if evidence of agranulocytosis or neutropenia is found in patients taking the drug.
    [Abstract] [Full Text] [Related] [New Search]